Personalized Cancer Treatment Systems with AI-Powered SN-38 Formulations

This inventive concept integrates poly(amino acid) block copolymer formulations of SN-38 with cutting-edge technologies like AI, IoT, blockchain, and nanomaterials to create personalized cancer treatment systems with enhanced efficacy and real-time monitoring capabilities.

The original patent disclosed formulations of SN-38 with poly(amino acid) block copolymers, but these formulations had limitations in terms of personalized dosing, real-time monitoring, and bioavailability. The new inventive concept addresses these limitations by incorporating synergistic combinations of distinct technologies to create a more powerful system.

The inventive concept comprises a poly(amino acid) block copolymer formulation of SN-38 integrated with machine learning algorithms for predicting optimal dosage regimens, IoT-enabled sensors for monitoring patient response, blockchain-based data management systems for secure and transparent data storage, and nanomaterials like graphene oxide nanoparticles for enhanced bioavailability. Additionally, AI-powered imaging analysis enables real-time tracking of SN-38 distribution and efficacy in the patient's body. The inventive concept also encompasses methods for optimizing SN-38 formulation composition using generative adversarial networks (GANs) and poly(amino acid) block copolymer libraries.

The new inventive concept introduces a synergistic combination of AI, IoT, blockchain, and nanomaterials with poly(amino acid) block copolymer formulations of SN-38, which is not obvious from the original patent. The integration of these distinct technologies provides a novel and non-obvious solution for personalized cancer treatment.

Alternative embodiments of the inventive concept could include the use of other machine learning algorithms, different types of IoT sensors, or various nanomaterials. Additionally, the inventive concept could be adapted for other types of cancer treatment or diseases.

The inventive concept has significant commercial potential in the cancer treatment market, particularly in the areas of personalized medicine and precision oncology. The target industries include pharmaceutical companies, healthcare providers, and medical research institutions.